New model links RNA editing glitch to early-stage type 1 diabetes

Hebrew University study proposes a new model suggesting that disrupted RNA editing within pancreatic beta cells might initiate an inflammatory response akin to early-stage type 1 diabetes.

MSD ventures into fibroblast therapies with $1.9bn deal with Mestag – Pharmaceutical Technology

Mestag’s pipeline consists of antibody therapies based on fibroblast-immune interactions as a treatment for cancer and inflammatory diseases. Image credit: Sergiy Palamarchuk / Shutterstock. MSD

October 9, 2024

Why many more people are lining up for a flu shot than a Covid vaccine

America is over the Covid vaccine. Frantic lineups for scarce doses when Covid vaccines first became available have long since given way to widespread indifference.

January 22, 2024

Leqembi gets closer to being offered as an injection

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. A bunch

May 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.